The Study
Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease
This study is like a school report that summarizes what other scientists have found. It doesn’t do a new experiment but tells us what happened in many past studies about a medicine called evolocumab. We can learn what those studies showed, but we can’t say this report by itself proves anything new.
Analysis score
Maximum 5 for a narrative review.
Where the score came from
Some people have bad cholesterol that’s too high, even when taking cholesterol pills. Evolocumab is a special shot that helps lower that bad cholesterol even more, especially when used with regular cholesterol medicine.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 52 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes, this is important.
- 2For people who’ve already had a heart problem, this medicine can help prevent another one and may help them live longer.
- 3Evolocumab cuts bad cholesterol by about 60%.
- 4It lowers the chance of heart attack, stroke, or dying from heart disease by 20%.
- 5Even at very low cholesterol levels (like 0.5 mmol/L), it’s still safe and keeps helping.
- 6One in 10 people might feel a little sting where the shot goes.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Reviews in Cardiovascular Medicine
Year
2024
Authors
L. Leiter, R. Hegele, Vivien Brown, Jean Bergeron, Erin S. Mackinnon, G. B. J. Mancini
Related Content
Claims (5)
Adding a drug called evolocumab to cholesterol-lowering statins can lower the chances of serious heart problems by 20% in people who already have heart disease.
When people with heart disease add a drug called evolocumab to their cholesterol medicine (statin), their bad cholesterol drops by about 60% quickly and stays low for years, helping most of them reach very low cholesterol goals that are hard to hit with statins alone.
For people who already have heart disease, adding evolocumab to their cholesterol medicine lowers their risk of heart attack, stroke, or dying from heart problems by about 1 in 5, and the protection gets stronger the longer they take it.
The lower the bad cholesterol gets with evolocumab, the lower the risk of heart problems—even when cholesterol drops to very low levels, there’s still added protection, and no ‘too low’ point has been found.
Evolocumab is very safe—even when used for over 8 years and when cholesterol drops to extremely low levels, it doesn’t cause serious side effects, diabetes, or memory problems. The only common issue is mild redness or soreness where the shot is given.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.